Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status
@article{Madhi2017VaccinationW1, title={Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status}, author={Shabir Ahmed Madhi and Anthonet L. Koen and Lisa Jose and Nadia van Niekerk and Peter V. Adrian and Clare L. Cutland and Nancy A. François and Javier Ruiz-Gui{\~n}az{\'u} and Juan Pablo Yarz{\'a}bal and Marta Moreira and Dorota Borys and Lode M Schuerman}, journal={Medicine}, year={2017}, volume={96} }
Background: Phase III, open-label, single-center, controlled study in South Africa (ClinicalTrials.gov: NCT00829010) to evaluate immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in human immunodeficiency virus (HIV)-infected (HIV+), HIV-exposed-uninfected (HEU), and HIV-unexposed-uninfected (HUU) children. Methods: Children stratified by HIV status received PHiD-CV primary vaccination (age 6/10/14…
16 Citations
Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa.
- Medicine, BiologyVaccine
- 2020
Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial
- MedicineExpert review of vaccines
- 2017
PHiD-CV was immunogenic when administered in different schedules and post‐booster responses suggest effective immunological priming with both 2‐ and 3‐dose primary series and support administration of the booster dose at 9–10 months of age.
Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children
- Biology, MedicineExpert review of vaccines
- 2017
While ART and pneumococcal conjugate vaccines (PCV) have reduced IPD morbidity and mortality in HIV-infected children, ART-naïve and immunosuppressed children have inferior immunogenicity to most PCV serotypes; highlighting the need for concomitant use of ART with PCV.
Decreased diarrheal and respiratory disease in HIV exposed uninfected children following vaccination with rotavirus and pneumococcal conjugate vaccines
- MedicinePloS one
- 2020
Significant declines in the burden of diarrheal and respiratory illness were observed among HEU children in Botswana following the introduction of RV and PCV, and these vaccines may maximally benefit HEUChildren in rural areas with higher disease burden.
Effect of Maternal Vaccination on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Study of PCV-10, PPV-23 or Placebo Administered during Pregnancy.
- Biology
- 2021
This study addressed secondary objectives of a double-blind, placebo-controlled, randomized trial of the safety, immunogenicity and transplacental transport of maternal antibodies after PNC vaccination of pregnant women with HIV, finding that maternal antibody levels in infants up to 8 weeks of life were higher than expected.
Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial
- MedicineHuman vaccines & immunotherapeutics
- 2018
Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and human rotavirus vaccine (HRV) when co-administered with RTS,S/AS01 in African infants had an acceptable safety profile.
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa
- MedicineVaccine
- 2019
Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children
- Medicine, BiologyExpert review of vaccines
- 2020
This review highlights that Synflorix vaccination has reduced the pneumococcal disease burden in young children in the last 10 years and continuous efforts are needed to improve access to pneumitiscal conjugate vaccines by increasing vaccination coverage in countries with ongoing pneumococal immunization programs.
Effect of 10-Valent Pneumococcal Conjugate Vaccine on Streptococcus pneumoniae Nasopharyngeal Carriage Among Children Less Than 5 Years Old: 3 Years Post-10-Valent Pneumococcal Conjugate Vaccine Introduction in Mozambique.
- Medicine, BiologyJournal of the Pediatric Infectious Diseases Society
- 2020
VT and antimicrobial non-susceptible pneumococci carriage dropped after PCV10 introduction, especially in HIV-uninfected children, however, VT carriage remained common, indicating ongoing VT pneumitisci transmission.
References
SHOWING 1-10 OF 35 REFERENCES
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.
- Medicine, BiologyThe New England journal of medicine
- 2003
Vaccination with a 9-valent pneumococcal conjugate vaccine reduced the incidence of radiologically confirmed pneumonia among children with and those without HIV infection.
Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection
- Medicine, BiologyAIDS
- 2014
Children with paHIV mount a robust serological response to PCV13 for most but not all vaccine serotypes, and Viral load suppression with HAART and higher baseline IgG concentration are associated with higher postvaccination antibody levels.
Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
- Medicine, BiologyBMC public health
- 2011
In sub-Saharan African infants, PHiD-CV was immunogenic for all vaccine pneumococcal serotypes and protein D, and vaccine tolerability was generally comparable between the PHid-CV and control groups.
Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.
- Medicine, BiologyThe Nigerian postgraduate medical journal
- 2013
Results suggest PHiD-CV can be co-administered with other vaccines included in the National Programme on Immunisation, and immunogenicity, reactogenicity and safety of the 10- valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine were evaluated in Nigeria.
Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.
- Medicine, BiologyVaccine
- 2013
Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children
- Medicine, BiologyHuman vaccines & immunotherapeutics
- 2013
A booster dose of PHiD-CV was well tolerated when administered to Malian children in the second year of life and was highly immunogenic for all 10 vaccine pneumococcal serotypes and NTHi protein D.
Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.
- Medicine, BiologyThe Lancet. Respiratory medicine
- 2014
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants.
- Medicine, BiologyThe Journal of infectious diseases
- 2010
Serotype-specific antibody concentration and opsonophagocytic activity (OPA) were evaluated after 3 doses of pneumococcal conjugate vaccine in HIV-noninfected infants born to HIV-seronegative or HIV-positive mothers and M-/I- infants had superior OPA responses, compared with those in HIV+/ART+ infants.
Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants.
- Medicine, BiologyJAMA
- 2011
Among South African infants, antenatal HIV exposure was associated with lower specific antibody responses in exposed uninfected infants compared with unexposed infants at birth, but with robust responses following routine vaccination.